J2KBIO Co., Ltd. (KOSDAQ:420570)
South Korea · Delayed Price · Currency is KRW 7,670.00
-350.00 (-4.36%)
At close: Nov 6, 2026
J2KBIO Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 43,899 | 32,966 | 33,129 | 28,472 | 16,032 | 14,219 |
Revenue Growth | 50.99% | -0.49% | 16.36% | 77.60% | 12.75% | 2.60% |
Gross Profit Gross Profit Growth | 17,401 | 12,979 | 12,657 | 11,502 | 7,058 | 5,929 |
Operating Income Operating Income Growth | 6,499 | 2,920 | 3,626 | 5,607 | 2,324 | 1,874 |
Net Income Net Income Growth | 5,814 | 2,673 | -1,653 | 4,844 | 2,086 | 1,623 |
Earnings Per Share EPS Growth | 994.22 | 458.84 | -299.50 | 978.27 | 414.44 | 26241.41 |
EPS Growth | 391.70% | - | - | 136.05% | -98.42% | 10.01% |
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Manufacturing and Sales of Cosmetic Raw Materials Manufacturing and Sales of Cosmetic Raw Materials Growth | 42,539 | 31,947 | 32,613 |
Clinical Service Clinical Service Growth | - | 1,020 | 515.98 |
Total Total Growth | 43,899 | 32,966 | 33,129 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 9,854 | 12,701 | 13,054 | 4,401 | 5,099 | 4,923 |
Total Debt Total Debt Growth | 989.7 | 1,135 | 2,088 | 1,246 | 4,590 | 5,248 |
Net Cash (Debt) Net Cash Growth | 8,864 | 11,566 | 10,966 | 3,156 | 508.96 | -324.19 |
Net Cash Growth | -4.03% | 5.48% | 247.50% | 520.00% | - | - |
Net Cash Per Share Net Cash Per Share Growth | 1515.79 | 1985.53 | 1987.27 | 625.86 | 100.95 | -5241.22 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 5,204 | 2,078 | 6,928 | 3,285 | 1,448 | 2,001 |
Capital Expenditures CapEx Growth | -383.73 | -866.78 | -6,904 | -1,369 | -119.66 | -798.8 |
Free Cash Flow Free Cash Flow Growth | 4,821 | 1,211 | 23.37 | 1,916 | 1,328 | 1,203 |
Free Cash Flow Growth | - | 5079.88% | -98.78% | 44.27% | 10.43% | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 39.64% | 39.37% | 38.20% | 40.40% | 44.02% | 41.70% |
Operating Margin | 14.80% | 8.86% | 10.95% | 19.69% | 14.49% | 13.18% |
Pretax Margin | 15.95% | 9.23% | -4.11% | 19.57% | 13.62% | 11.21% |
Profit Margin | 13.24% | 8.11% | -4.99% | 17.01% | 13.01% | 11.42% |
FCF Margin | 10.98% | 3.67% | 0.07% | 6.73% | 8.28% | 8.46% |
Fiscal Year | Current | FY 2025 | FY 2024 |
|---|---|---|---|
| Period Ending | Nov '26 Nov 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Dividend Per Share Dividend Per Share Growth | 250.000 | 250.000 | 200.000 |
Dividend Per Share Growth | 0% | 25.00% | - |
Dividend Yield | 3.26% | 2.91% | 2.21% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 7.71 | 18.82 | - | - | - | - |
P/FCF Ratio | 9.73 | 41.54 | 2224.56 | - | - | - |
PS Ratio | 1.07 | 1.53 | 1.57 | - | - | - |